Regenerative cells' ability to differentiate and secrete trophic factors has important potential for tissue regeneration and repair.
Regenerative medicine was found to produce improvement in a large study of patients with rheumatoid arthritis according to validated questionnaires.
Local injection of mesenchymal cells has been shown to improve joint function due to stem cells’ ability to repair and regenerate cartilage tissue.
Immunomodulation is a key property of regenerative cells that allows them not to elicit a patient immune response. Studies show that umbilical cord cells are safe and comparable to bone marrow-derived cells, with great potential for therapeutic use.
Differentiation abilities allow cells to replace heart muscle cells that have been damaged by cardiovascular disease, improving heart muscle ability.
Documented use of cells for diabetes patients includes boosting insulin-producing cells and reversing certain complications.
Several studies have shown that cells benefit patients with the autoimmune disease lupus.
Several studies have shown that regenerative medicine has antimicrobial potential.
A study of Parkinson’s patients has demonstrated medium-term improvement with regenerative therapy.
Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinson-s disease. Venkataramana NK et al. Translational Research. 2010 Feb. Abstract
Stem cells have been shown to improve organ acceptance in kidney transplant.
Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Perico N et al. Transplant International. 2013 Sep. Abstract
This website is intended to inform and educate medical professionals. It is NOT intended for patients. It also does not seek to make claims about the effectiveness of regenerative medicine and its respective therapies in medical treatment.
Regenerative therapies have great potential in helping treat a range of conditions. This site serves to inform medical professionals about regenerative medicine, BioGenix allograft products, and key in vitro, animal model, and clinical research studies that have been carried out to date across medical specialties and health conditions. However, regenerative medicine is an early and evolving field, and clinical studies are still insufficient to determine effectiveness.
While the BioGenix products are produced in an FDA compliant laboratory, it has not been approved by the FDA for treatment effectiveness. The FDA states:
Like other medical products that are intended to treat, cure or prevent disease, generally require FDA approval before they can be marketed. FDA has not approved any stem cell-based products for use, other than cord blood-derived hematopoietic progenitor cells (blood-forming stem cells) for certain indications.
Patients interested in regenerative therapy in the U.S. are advised to consult a physician about the state of FDA approval for any given product and/or inquire about opportunities to participate in a clinical trial. Patients interested in regenerative therapies outside the U.S. should investigate regulations in the specific country. It is important to be aware that regulations and clinical study requirements vary from country to country.
By clicking yes you confirm that you are a medical professional, understand that the information contained in this website is intended for medical professionals and not for the general public, and have read and understood the disclaimer above.